Page 210 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Cost-effectiveness of nivolumab+chemo for gastric/GEJ cancer

cisplatin with or without cetuximab for patients with line treatment for metastatic NSCLC that expresses high
previously untreated advanced gastric cancer (EXPAND): levels of PD-L1 in the United States. Pharmacoeconomics.
A randomised, open-label phase 3 trial. Lancet Oncol. 2017;35(8):831-844.
2013;14(6):490-499.
doi: 10.1007/s40273-017-0527-z
doi: 10.1016/S1470-2045(13)70102-5
19. Lin S, Luo S, Zhong L, et al. Cost-effectiveness of
10. Shah MA, Bang YJ, Lordick F, et al. Effect of fluorouracil, atezolizumab plus chemotherapy for advanced non-small-
leucovorin, and oxaliplatin with or without onartuzumab cell lung cancer. Int J Clin Pharm. 2020;42(4):1175-1183.
in HER2-negative, MET-positive gastroesophageal
adenocarcinoma: The METGastric randomized clinical doi: 10.1007/s11096-020-01076-3
trial. JAMA Oncol. 2017;3(5):620-627. 20. Sanders GD, Neumann PJ, Basu A, et al. Recommendations
for conduct, methodological practices, and reporting of cost-
doi: 10.1001/jamaoncol.2016.5580
effectiveness analyses: Second panel on cost-effectiveness in
11. Ando K, Kishino Y, Homma T, et al. Nivolumab plus health and medicine. JAMA. 2016;316(10):1093-1103.
ipilimumab versus existing immunotherapies in patients
with PD-L1-positive advanced non-small cell lung cancer: doi: 10.1001/jama.2016.12195
A systematic review and network meta-analysis. Cancers. 21. Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness
2020;12(7):1905. thresholds: The past, the present and the future.
doi: 10.3390/cancers12071905 Pharmacoeconomics. 2018;36(5):509-522.
12. Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, doi: 10.1007/s40273-017-0606-1
everolimus, nivolumab, sunitinib and best supportive care in 22. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced
previously treated renal cell carcinoma: A systematic review secondary analysis of survival data: Reconstructing the data
and economic evaluation. Health Technol Assess Winch Engl. from published Kaplan-Meier survival curves. BMC Med
2018;22(6):1-278. Res Methodol. 2012;12:9.
doi: 10.3310/hta22060 doi: 10.1186/1471-2288-12-9
13. Janjigian YY, Shitara K, Moehler M, et al. First-line 23. Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-
nivolumab plus chemotherapy versus chemotherapy effectiveness analysis of ceritinib and alectinib versus
alone for advanced gastric, gastro-oesophageal junction, crizotinib in the treatment of anaplastic lymphoma kinase-
and oesophageal adenocarcinoma (CheckMate 649): positive advanced non-small cell lung cancer. Cancer Manag
A randomised, open-label, phase 3 trial. Lancet Lond Engl. Res. 2019;11:9195-9202.
2021;398(10294):27-40.
doi: 10.2147/CMAR.S223441
doi: 10.1016/S0140-6736(21)00797-2
24. Wang X, Jin L, Cui J, Ma K, Chen X, Li W. Mouse double
14. Verma V, Sprave T, Haque W, et al. A systematic review of the minute-2 homolog (MDM2)-rs2279744 polymorphism
cost and cost-effectiveness studies of immune checkpoint associated with lung cancer risk in a Northeastern Chinese
inhibitors. J Immunother Cancer. 2018;6(1):128. population. Thorac Cancer. 2015;6(1):91-96.
doi: 10.1186/s40425-018-0442-7 doi: 10.1111/1759-7714.12153
15. Bullement A, Latimer NR, Bell Gorrod H. Survival 25. Zhang L, Zeng X, Cai H, et al. Cost-effectiveness of second-
extrapolation in cancer immunotherapy: A validation- line nivolumab for platinum-treated advanced non-small-
based case study. Value Health J Int Soc Pharmacoeconomics cell lung cancer. J Comp Eff Res. 2020;9(18):1301-1309.
Outcomes Res. 2019;22(3):276-283.
doi: 10.2217/cer-2020-0053
doi: 10.1016/j.jval.2018.10.007
26. Chen HD, Zhou J, Wen F, et al. Cost-effectiveness analysis of
16. Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. apatinib treatment for chemotherapy-refractory advanced
Accounting for cured patients in cost-effectiveness analysis. gastric cancer. J Cancer Res Clin Oncol. 2017;143(2):361-368.
Value Health J Int Soc Pharmacoeconomics Outcomes Res.
2017;20(4):705-709. doi: 10.1007/s00432-016-2296-z
doi: 10.1016/j.jval.2016.04.011 27. Wang SJ, Fuller CD, Choi M, Thomas CR. A cost-effectiveness
analysis of adjuvant chemoradiotherapy for resected gastric
17. Yang P. Epidemiology of lung cancer prognosis: Quantity and cancer. Gastrointest Cancer Res GCR. 2008;2(2):57-63.
quality of life. Methods Mol Biol Clifton NJ. 2009;471:469-486.
28. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-
doi: 10.1007/978-1-59745-416-2_24 effectiveness of treatment and endoscopic surveillance of
18. Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of precancerous lesions to prevent gastric cancer. Cancer.
pembrolizumab vs. standard-of-care chemotherapy as first- 2010;116(12):2941-2953.

Volume 9 Issue 1 (2025) 202 doi: 10.36922/ejmo.7075